Compare EPR Properties (EPR) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Revvity Inc — how do they compare? EPR Properties trades at $54.8 (market cap $4.17B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 4.1× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.84%). Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 46 Days and Revvity Inc for 12 Days on average.
| EPR | RVTY | |
|---|---|---|
Market Cap | $4.17B | $16.98B |
Volume | 992,716 | 1,456,900 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $157.36 |
52-Week Low | $48.71 | $82.26 |
Typical Hold Time | 46 Days | 12 Days |
Enterprise Value | $7.68B | $19.30B |
Dividend Yield | 6.84% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $55.03, up 1.76% today, with a bearish technical signal but oversold RSI suggesting potential reversal. The REIT reported strong Q2 2026 EPS beat ($0.79 vs. $0.745 expected) and maintains a high gross margin of 91.41%. Recent news highlights its 6.5% dividend yield and diversification into theme parks and experiential properties, though 2026 net income is projected to decline to $263 million.
The stock offers value with a forward P/E of 17.44 and consensus price target of $65.50, implying 19% upside. Key risks include declining 2026 profitability, high leverage exposure, and sensitivity to interest rates. Analyst sentiment is mixed with 32% buy ratings, but institutional buying and oversold conditions support a cautious bullish outlook for income-focused investors.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
